LNB
IONS icon

Ledyard National Bank’s Ionis Pharmaceuticals IONS Stock Holding History

Ledyard National Bank’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-166
Closed -$8K – 825
2017
Q3 		$8K Buy
+166
New +$8.7K ﹤0.01% 676

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Ledyard National Bank's IONS Position: Q4 2017 in Review

Ledyard National Bank sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 166 shares — an estimated $8K sold.

Ledyard National Bank first reported a position in IONS in Q3 2017 and held it in 1 quarter. The position peaked at $8K in Q3 2017. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

  • Ledyard National Bank reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Ledyard National Bank sold 166 Ionis Pharmaceuticals shares in Q4 2017, an estimated $8K.
  • Ledyard National Bank first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Ledyard National Bank's Ionis Pharmaceuticals position peaked at $8K in Q3 2017.
  • 316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Ledyard National Bank's 13F filing for Q4 2017, filed 30 Jan 2018.